ANGLE plc is a medical diagnostic company focusing on cancer diagnostics and fetal health. The company’s lead product, the Parsortix cell separation system, can capture rare cells from blood, including circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in 1 billion healthy cells. The resulting liquid biopsy enables the investigation of mutations in the patient’s cancer for personalized cancer care. ANGLE has launched a product for the research market and has secured CE Mark regulatory approval for the clinical market in Europe. The FDA authorization is in process. For more information visit the company’s website at www.angleplc.com